News

1 to 9 of 96972 results

AstraZeneca signs drug discovery collaboration with Cancer Research UK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

28-11-2014

UK pharma major AstraZeneca and charity Cancer Research UK have signed a memorandum of understanding…

AstraZenecaOncologyPharmaceuticalResearchUK

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

Spanish physicians’ understanding of biosimilars: ASBM survey

28-11-2014

The Alliance for Safe Biologic Medicines (ASMB) presented results from a survey of European physicians…

BiosimilarsBiotechnologyHealthcareMarkets & MarketingSpain

Cocrystal Pharma and RFS Pharma complete merger

28-11-2014

USA-based biotech firm Cocrystal Pharma has announced the closing of its merger with RFS Pharma, a privately…

Anti-viralsBiotechnologyCocrystal PharmaMergers & AcquisitionsRFS Pharma

Asthma drug market set to grow $23 billion by 2023

28-11-2014

The asthma treatment market value will grow across eight major countries (the USA, UK, France, Germany,…

AdvairAstraZenecaAustraliaEuropeGlaxoSmithKlineJapanMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicortUSA

Global oncology biosimilars market 2014-2018

28-11-2014

The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR)…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingMylanSandoz

Teva appoints Yitzhak Peterburg as chairman of the board

Teva appoints Yitzhak Peterburg as chairman of the board

27-11-2014

Israel-based Teva Pharmaceuticals has appointed Yitzhak Peterburg as chairman of the board of directors.

BoardroomIsraelPharmaceuticalTevaTeva Pharmaceuticals

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

27-11-2014

The UK National Institute for Health and Care Excellence (NICE) has today issued final draft guidance…

Alexion PharmaceuticalsBiotechnologyPricingRare diseasesRegulationSolirisUK

1 to 9 of 96972 results

Parexel

Parexel

Back to top